Key facts
- It has raised $4.2M.
- Notable investors include 000 Startups-NASSCOM, 10, Aeravti Ventures, Micro Labs (Pharmaceuticals), Startup Haryana.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for East Ocyon Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for East Ocyon Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About East Ocyon Bio
Developer of cell and gene therapy designed for cancer treatment. The company's proprietary therepy modifies natural killer cells using synthetic biology and non-viral cell engineering to create an allogeneic chimeric antigen receptor that targets both solid and blood-based tumors by enhancing immune response and tumor recognition, providing doctors with advanced treatment options for various types of cancer.
- Sector
- Healthcare
- HQ
- Gurugram, India
- Founded
- 2022
- Employees
- 27
- Website
- eastocyonbio.com/
- Ownership
- Privately Held (backing)
East Ocyon Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in East Ocyon Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on East Ocyon Bio in its N-PORT filings yet. We sweep new filings monthly.